Radiopharm Theranostics (NASDAQ:RADX) Coverage Initiated by Analysts at HC Wainwright

Equities research analysts at HC Wainwright initiated coverage on shares of Radiopharm Theranostics (NASDAQ:RADX) in a research report issued to clients and investors on Thursday,Benzinga reports. The firm set a “buy” rating and a $16.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 256.35% from the company’s previous close.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.00.

Radiopharm Theranostics Trading Down 1.3%

RADX opened at $4.49 on Thursday. The firm’s fifty day moving average is $4.48 and its two-hundred day moving average is $4.80. Radiopharm Theranostics has a twelve month low of $3.62 and a twelve month high of $16.25.

Institutional Investors Weigh In On Radiopharm Theranostics

A number of hedge funds and other institutional investors have recently made changes to their positions in RADX. Marex Group plc acquired a new stake in shares of Radiopharm Theranostics during the fourth quarter worth $54,000. Virtu Financial LLC bought a new position in Radiopharm Theranostics in the fourth quarter valued at $76,000. Jane Street Group LLC bought a new position in Radiopharm Theranostics in the fourth quarter valued at $76,000. PNC Financial Services Group Inc. grew its position in Radiopharm Theranostics by 100.0% in the third quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock valued at $88,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in Radiopharm Theranostics in the fourth quarter valued at $1,007,000.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.